Picard Medical / SynCardia to Present Next Generation Total Artificial Heart Platform at ISHLT 2026 in Toronto
Rhea-AI Summary
Picard Medical (NYSE American: PMI) will present SynCardia’s next-generation total artificial heart platform at ISHLT 2026 in Toronto on April 24, 2026. The poster, titled “The Emperor Total Artificial Heart: A Fully Implantable Solution for End Stage Heart Failure”, highlights ongoing development of a fully implantable TAH.
SynCardia will also exhibit at booth 409, offering clinicians and attendees information on the SynCardia Total Artificial Heart and efforts to expand access to life‑sustaining therapies.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – PMI
On the day this news was published, PMI declined 3.07%, reflecting a moderate negative market reaction. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $67.91M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 15 | Clinical case highlight | Positive | -1.8% | Reported successful bridge-to-transplant case using SynCardia Total Artificial Heart. |
| Apr 02 | Conference keynote | Positive | -9.4% | Announced COO keynote on next-gen fully implantable heart at AZ Tech Week. |
| Apr 01 | Patient event | Positive | +1.0% | Planned Voice of the Patient event spotlighting advanced heart failure experiences. |
| Mar 25 | Full-year earnings | Neutral | +3.0% | Reported 2025 revenue growth, higher cash, but wider net loss and need for capital. |
| Mar 20 | Conference data | Positive | +2.7% | Planned presentation of early preclinical Emperor Total Artificial Heart data at ACC. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has often focused on clinical milestones and conference visibility. Reactions have been mixed, with some positive clinical or presentation news followed by share price declines, while earnings and certain conference updates have coincided with modest gains.
Over the last month, PMI has repeatedly highlighted its SynCardia Total Artificial Heart and next‑generation Emperor platform through clinical case reports, conference presentations, and investor communications. Notable items include full‑year 2025 financial results with higher revenue but ongoing losses, multiple high-profile conference appearances, and bridge‑to‑transplant success cases at major centers. Today’s ISHLT 2026 announcement continues this pattern of emphasizing clinical engagement and innovation rather than introducing new financial or regulatory developments.
Regulatory & Risk Context
Key Terms
total artificial heart medical
end stage heart failure medical
biventricular heart failure medical
mechanical circulatory support medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Picard to showcase the SynCardia TAH and next-generation innovation
TUCSON, Ariz., April 16, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard Medical” or the “Company”), parent company of SynCardia Systems, LLC, (“SynCardia”) maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced its participation in the International Society for Heart and Lung Transplantation (“ISHLT”) 2026 Annual Meeting, to be held at the Metro Toronto Convention Centre in Toronto, Canada.
The ISHLT Annual Meeting is a leading global forum for clinicians, researchers and industry participants focused on the treatment of advanced heart and lung failure, featuring the latest clinical data, emerging technologies and advances in transplantation and mechanical circulatory support.
Andre R. Simon, Vice President of Clinical Affairs at SynCardia, will present a poster titled, “The Emperor Total Artificial Heart: A Fully Implantable Solution for End Stage Heart Failure” during the Total Artificial Heart and Emerging Circulatory Support Technologies poster session. The presentation will highlight ongoing development of the next-generation, fully implantable total artificial heart platform.
- Date: April 24, 2026
- Time: 4:30 p.m. to 5:30 p.m.
- Location: Poster Hall
In addition to the scientific presentation, SynCardia will exhibit at booth 409, where attendees can learn more about the SynCardia Total Artificial Heart and ongoing efforts to expand access to life sustaining therapies for patients with end stage biventricular heart failure.
Participation in ISHLT 2026 underscores Picard Medical’s continued engagement with the global clinical community and its commitment to advancing innovation in mechanical circulatory support through scientific exchange and collaboration.
About The International Society for Heart and Lung Transplantation
ISHLT is a global, multidisciplinary professional organization dedicated to improving outcomes for patients with advanced heart and lung disease through transplantation, mechanical circulatory support, and innovative therapies. Founded in 1981, ISHLT brings together more than 3,600 members across over 60 countries, including physicians, researchers and allied health professionals, and serves as a leading forum for advancing clinical science, professional standards and education in the field.
About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the STAH is the most widely used and extensively studied artificial heart in the world. For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”) at www.sec.gov.
Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Additional information about the Company, including risk factors that may affect the Company’s business, financial condition, and results of operations, is contained in the Company's filings with the SEC, including the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available free of charge on the SEC’s website at http://www.sec.gov and on the Company's investor relations website at https://picardmedical.com/.
Contact:
Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com
Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com
General/Media
Brittany Lanza
blanza@syncardia.com
